Mineralys Therapeutics Stock (NASDAQ:MLYS)
Previous Close
$11.59
52W Range
$5.85 - $16.91
50D Avg
$12.17
200D Avg
$11.79
Market Cap
$584.79M
Avg Vol (3M)
$227.87K
Beta
2.46
Div Yield
-
MLYS Company Profile
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.